

Supplementary Materials:

Biological activities of cyclic and acyclic B-type laxaphycins in SH-SY5Y human neuroblastoma cells

Rebeca Alvariño¹, Eva Alonso^{1,2 *}, Louis Bornancin³, Isabelle Bonnard^{3,4}, Nicolas Inguibert^{3,4}, Bernard Banaigs^{3,4} and Luis M Botana¹

Figure S1. ¹H-NMR spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (5) in DMSO (303K) **Figure**

S2. ¹³C-NMR spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (5) in DMSO (303K) **Figure S3.**

DEPT135-NMR spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (5) in DMSO (303K) **Figure S4.**

TOCSY spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (5) in DMSO (303K)

Figure S5. ROESY spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (5) in DMSO (303K)

Figure S6. HSQC spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (5) in DMSO (303K)

Figure S7. HSQC-TOCSY spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (5) in DMSO (303K)

Figure S8. HMBC spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (5) in DMSO (303K)

Figure S9. ¹H-NMR spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (6) in DMSO (303K) **Figure**

S10. ¹³C-NMR spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (6) in DMSO (303K) **Figure S11.**

DEPT135-NMR spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (6) in DMSO (303K) **Figure S12.**

TOCSY spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (6) in DMSO (303K) **Figure S13.** ROESY

spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (6) in DMSO (303K) **Figure S14.** HSQC

spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (6) in DMSO (303K) **Figure S15.** HSQC-TOCSY

spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (6) in DMSO (303K) **Figure S16.** HMBC

spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (6) in DMSO (303K)




Figure S1. $^1\text{H-NMR}$ spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (**5**) in DMSO (303K)




Figure S2. $^{13}\text{C-NMR}$ spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (**5**) in DMSO (303K)




Figure S3. DEPT135-NMR spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (**5**) in DMSO (303K)




Figure S4. TOCSY spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (**5**) in DMSO (303K)




Figure S5. ROESY spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (**5**) in DMSO (303K)




Figure S6. HSQC spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (**5**) in DMSO (303K)




Figure S7. HSQC-TOCSY spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (**5**) in DMSO (303K)




Figure S8. HMBC spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B (**5**) in DMSO (303K)




Figure S9. ^1H -NMR spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (**6**) in DMSO (303K)




Figure S10. ^{13}C -NMR spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (**6**) in DMSO (303K)




Figure S11. DEPT135-NMR spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (**6**) in DMSO (303K)




Figure S12. TOCSY spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (**6**) in DMSO (303K)




Figure S13. ROESY spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (**6**) in DMSO (303K)




Figure S14. HSQC spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (**6**) in DMSO (303K)




Figure S15. HSQC-TOCSY spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (**6**) in DMSO (303K)




Figure S16. HMBC spectrum of [des-(Ala⁴-Hle⁵)] acyclolaxaphycin B3 (**6**) in DMSO (303K)